Please use this identifier to cite or link to this item: http://ir.swu.ac.th/jspui/handle/123456789/14379
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLertdumrongluk P.
dc.contributor.authorChangsirikulchai S.
dc.contributor.authorLimkunakul C.
dc.contributor.authorPrachukthum P.
dc.contributor.authorPunpiput P.
dc.contributor.authorBuppanharun R.
dc.contributor.authorChotpitayasunondh C.
dc.date.accessioned2021-04-05T03:34:28Z-
dc.date.available2021-04-05T03:34:28Z-
dc.date.issued2012
dc.identifier.issn0264410X
dc.identifier.other2-s2.0-84856314678
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84856314678&doi=10.1016%2fj.vaccine.2011.12.023&partnerID=40&md5=e53457e2ed772a7e30543b18e72af048
dc.identifier.urihttp://ir.swu.ac.th/jspui/handle/123456789/14379-
dc.description.abstractA worldwide vaccination campaign against the 2009 pandemic influenza A (H1N1) virus was launched among high-risk subjects, including hemodialysis patients. The long-term immunogenicity of an influenza vaccine has not been investigated in hemodialysis patients. This study aimed to (1) assess the long-term immunogenicity of a monovalent non-adjuvanted influenza A (H1N1) vaccine in hemodialysis patients and (2) determine the safety of this vaccine. We conducted a prospective cohort study of 44 hemodialysis patients and 149 healthy controls in 2010. All of the participants received a single dose of the monovalent non-adjuvanted 2009 influenza A (H1N1) vaccine. The level of antibodies was measured at baseline and at 4 and 24 weeks post-vaccination using a hemagglutination inhibition assay. The outcomes were the percentages of participants who achieved seroconversion and seroprotection (titer ≥1:40) 4 and 24 weeks after vaccination. At 4 weeks post-vaccination, seroconversion was observed in 17 (38.6%) of the hemodialysis patients and 94 (63.1%) of the controls (P= 0.056), and protective titers were obtained in 22 (50%) of the hemodialysis patients and 100 (67.1%) of the controls (P= 0.426). At 24 weeks post-vaccination, immunogenicity decreased in both the hemodialysis patients and the controls, but there were no significant differences between the hemodialysis patients and the controls in the seroconversion rate (27.3% versus 36.9%, P= 0.526) or the seroprotection rate (38.6% versus 48.3%, P= 0.996). No differences in adverse events were observed between the hemodialysis patients and the controls. In summary, the 2009 influenza A (H1N1) vaccine elicits a similar immune response in both hemodialysis patients and healthy controls, but immunity declines 24 weeks after vaccination in both groups. Hemodialysis patients should at least be vaccinated annually against the influenza virus. © 2011 Elsevier Ltd.
dc.subjectinfluenza vaccine
dc.subjectvirus antibody
dc.subject2009 H1N1 influenza
dc.subjectadult
dc.subjectaged
dc.subjectantibody blood level
dc.subjectantibody response
dc.subjectantibody titer
dc.subjectarticle
dc.subjectchill
dc.subjectcontrolled study
dc.subjectdrug safety
dc.subjectfemale
dc.subjectfever
dc.subjectheadache
dc.subjecthemagglutination inhibition
dc.subjecthemodialysis patient
dc.subjecthigh risk patient
dc.subjecthuman
dc.subjectimmunogenicity
dc.subjectinjection site contusion
dc.subjectinjection site erythema
dc.subjectinjection site pain
dc.subjectinjection site swelling
dc.subjectmajor clinical study
dc.subjectmalaise
dc.subjectmale
dc.subjectmyalgia
dc.subjectnausea
dc.subjectpriority journal
dc.subjectprospective study
dc.subjectrash
dc.subjectseroconversion
dc.subjectseroprotection
dc.subjecttreatment outcome
dc.subjectvirus immunity
dc.subjectAdult
dc.subjectAged
dc.subjectAntibodies, Viral
dc.subjectCohort Studies
dc.subjectHemagglutination Inhibition Tests
dc.subjectHumans
dc.subjectInfluenza A Virus, H1N1 Subtype
dc.subjectInfluenza Vaccines
dc.subjectInfluenza, Human
dc.subjectMiddle Aged
dc.subjectProspective Studies
dc.subjectRenal Dialysis
dc.subjectTime Factors
dc.subjectTreatment Outcome
dc.titleSafety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationVaccine. Vol 30, No.6 (2012), p.1108-1114
dc.identifier.doi10.1016/j.vaccine.2011.12.023
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.